StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) bonds

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Kalaris Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Kalaris Therapeutics's 10-Q for the period ended Jun 30, 2026

IssueCouponAmount issuedCarrying value
2024 Convertible Promissory Note
Convertible at $6 a share
10.00%$10.00M$0
2025 Bridge Notes–$3.75M–
January 2025 AlloVir Convertible Promissory Note
Convertible
–$3.75M–

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawn
2024 Bridge Notes$15.00M$0

See a number that looks wrong?